Preparing for JPM? Look At Who You Could Meet At RESI San Francisco

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, VP of Investor Research, LSN

Many of us in the biotech world are already planning out our time at the annual San Francisco conference week in January, and early stage investors are no exception. Many have already put their names down for RESI San Francisco – which is no surprise, as over 500 investors registered for this event in 2018! See below for some of the investors who will be coming to the 2019 event.

LSN held our first RESI San Francisco event in 2015. Previously, LSN staff had attended San Francisco’s annual healthcare week and noticed that the events there all focused on later-stage companies and the public biotech markets; there was no real, focused venue for early stage startups and early stage investors to meet. We therefore brought RESI to San Francisco, and have often heard from players in the early stage world that it’s filled a real need amid the hectic conference week. We hope you can join us there on January 8th, 2019.

CONFIRMED INVESTORS AND STRATEGIC PARTNERS

As of October 25th, 2018

And More…

Hot Investor Mandate: USA-Based VC Firm Invests Up to $10M in First-In-Class Therapeutics and AI-Based Technologies

~ Next Phase Admin ~ Leave a comment

A VC firm based in CA invests in companies in Consumer & FinTech, Blockchain, Enterprise & Big Data as well as Life Science & Digital Health. For companies in the life sciences, the firm generally invests in Series A-C rounds, committing between $1-10M in capital. The firm is willing to invest in both the US and China, and will consider companies in pre-clinical and clinical development.

Within the life sciences, the firm is willing to invest in therapeutics, diagnostics, medtech, digital health and R&D services. For therapeutics, the firm will consider traditional therapeutics that are first-in-class, either a novel target or novel therapeutic, but is agnostic to indication. For diagnostics, medtech, digital health and R&D services, the firm focuses on AI-based technologies. Previous investments include AI-based drug discovery platforms, pathology screening, diagnostic services and care management platforms.

The firm looks for companies with a strong management team, large market opportunity and a disruptive technology. When investing, the firm is willing lead or co-invest, and will occasionally take a board seat after investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Private Investment Firm Invests in Early-Stage Healthcare Companies, with Strong Interests in Digital Health, Informatics, Novel Therapeutics

~ Next Phase Admin ~ Leave a comment

A private investment firm founded and based in California, USA invests in seed and early-stage health technology companies. The typical investment size for seed investment ranges from $250K to $1M (usually in equity or convertible notes). For early-stage companies, the firm typically co-invests with other VC firms in Seed and Series A financing and the investment size will depend on the company’s financial needs. The firm is geographically agnostic but prefers start-ups to be based on the West Coast. The firm is actively seeking new investment opportunities.

Historically, the firm has invested in technology and life sciences, with notable biotech investments in Amgen and Biogen. Today, the firm has a focus on the digital health and informatics space, but also invests in novel therapeutics. The firm is agnostic in terms of subsectors and indications, including orphan indications. The firm will only consider technologies with proof of concept and strong scientific rationale. Historically, the firm has invested in therapeutics that address oncology, infectious diseases, cardiovascular, and metabolic disorders; drug delivery; orthopedic devices; genomics.

The firm takes a board seat in some cases, and prefers to syndicate on opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Newly Established VC Firm Focuses on USA Companies Working on Technologies that Enhance Human Experience & Well-Being

~ Next Phase Admin ~ Leave a comment

A newly established venture capital firm is focused on technologies that enhance the human experience and contribute to their well-being. For initial investment, the firm will invest $100-500K and will reserve some funds for follow-on investment. The firm invests mainly in Seed to Series A rounds and often acts as the first institutional investor. Currently, the firm is focused on investing in companies based in the USA, and aims to make 8-10 investments in bio/healthcare technologies.

The firm is interested in companies dedicated to genetics, microbiome, personal pharmaceuticals/diagnostics, VR/AR, consumer-facing medtech or digital health technologies, etc. The firm does not invest in traditional biopharmaceuticals or medical devices, but open to those that require 510k approval.

The firm is open to working with all types of management teams and has no specific management requirements. They could lead the round at seed stage but typically syndicate with other investors for Series A. The firm will take an active role in supporting their companies with needed guidance and resources.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Fund Focuses Investments on Medical Devices, Therapeutics, and Diagnostics Companies Looking to Expand to the China Market

~ Next Phase Admin ~ Leave a comment

A VC fund is focused on the earliest stage companies looking to expand to the Chinese market. The firm will invest between $50-250K in companies that are preclinical/in development and looks to be a strategic partner, either by helping the company enter the Chinese market, or find a licensing opportunity with one of the firm’s strategic partners in China. The firm is looking for therapeutic, medical device or diagnostics companies, but will generally not consider digital health companies due to the difficulty in adapting them to the Chinese market. The firm is currently looking to make about 4 investments a year, about 1 per quarter.

The firm is currently focused primarily on medical devices, but will consider therapeutics and diagnostics as well. For medical devices, the firm prefers 510k pathway. The firm is generally agnostic to subsector and indication, but is seeking technologies that are relevant to the Chinese market.

While it is not required, the firm prefers to take a board seat after investing, since they are looking to be active strategic partners in each company in which the firm invests.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI NYC Announces Innovation Challenge Finalists

~ Next Phase Admin ~ Leave a comment

By Karen Deyo, Investor Research Analyst, LSN

RESI NYC is just over 2 weeks away, on Monday, November 5th, and we are happy to announce the thirty finalists for the RESI Innovation Challenge. The Innovation Challenge finalists span from therapeutics to medical devices to diagnostics and digital health. The Innovation Challenge is designed to allow the finalists a chance to showcase their technology to the investors and strategic partners attending RESI, beyond the one-on-one Partnering Forum – make sure to stop by and look at their innovative technologies! Each attendee will receive “RESI Cash” to “invest” in their favorite company (or companies). The top three companies will receive prizes at the end of the day, so make sure to go through the exhibit hall and check out all of the IC Finalist posters!

Thank you to all of the amazing companies that applied to the Innovation Challenge – it is exciting to see what new technologies could soon be reaching market. See you in New York City!

Therapeutic

 

Diagnostic

 

MedTech Device

 

Digital Health

RESI Returns to San Francisco on January 8th 2019

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, VP of Investor Research, LSN

It’s only October, but the annual San Francisco healthcare week in January feels just around the corner.  On Tuesday January 8th, RESI will return to the Union Square fray with a 1-day event packed with one-on-one meetings, networking and content for life science entrepreneurs.  Last year, this event attracted over 500 early stage investors – and we’ve often heard from attendees that if you’re headed to JPM, there’s no better place than RESI for venture-stage companies to look for financing.

If you’d like to join our largest event of the year, register here.